We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
- Authors
Papazisis, Konstantinos T; Kontovinis, Lukas F; Papandreou, Christos N; Kouvatseas, George; Lafaras, Christos; Antonakis, Evangelos; Christopoulou, Maria; Andreadis, Charalambos; Mouratidou, Despoina; Kortsaris, Alexandros H
- Abstract
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that has been approved for the treatment of metastatic renal cell carcinoma. Although the majority of sunitinib-treated patients receive a clinical benefit, almost a third of the patients will not respond. Currently there is no available marker that can predict for response in these patients.
- Publication
BMC cancer, 2010, Vol 10, p489
- ISSN
1471-2407
- Publication type
Journal Article
- DOI
10.1186/1471-2407-10-489